Armata Total Current Liabilities from 2010 to 2024

ARMP Stock  USD 4.10  0.06  1.49%   
Armata Pharmaceuticals Total Current Liabilities yearly trend continues to be relatively stable with very little volatility. Total Current Liabilities is likely to grow to about 17.3 M this year. Total Current Liabilities is the total amount of liabilities that Armata Pharmaceuticals is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
1993-12-31
Previous Quarter
21.9 M
Current Value
16.5 M
Quarterly Volatility
7.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 2.8 M or Selling General Administrative of 11.1 M, as well as many exotic indicators such as Price To Sales Ratio of 24.52, Dividend Yield of 0.0175 or Operating Cycle of 137. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Armata Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Armata Pharmaceuticals Technical models . Check out the analysis of Armata Pharmaceuticals Correlation against competitors.
To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Latest Armata Pharmaceuticals' Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Armata Pharmaceuticals over the last few years. Total Current Liabilities is an item on Armata Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Armata Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Armata Pharmaceuticals' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Slightly volatile
   Total Current Liabilities   
       Timeline  

Armata Total Current Liabilities Regression Statistics

Arithmetic Mean6,533,070
Geometric Mean4,105,768
Coefficient Of Variation109.53
Mean Deviation5,225,436
Median3,580,000
Standard Deviation7,155,790
Sample Variance51.2T
Range24M
R-Value0.73
Mean Square Error25.6T
R-Squared0.53
Significance0
Slope1,170,244
Total Sum of Squares716.9T

Armata Total Current Liabilities History

202417.3 M
202316.5 M
202224.9 M
20214.8 M
20206.7 M
20194.9 M
20182.6 M

About Armata Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Armata Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Armata Pharmaceuticals investors use historical funamental indicators, such as Armata Pharmaceuticals's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Armata Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Armata Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Armata Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Armata Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Total Current Liabilities16.5 M17.3 M

Pair Trading with Armata Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Armata Stock

  0.55CVS CVS Health Corp Financial Report 1st of May 2024 PairCorr
  0.51MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.48MDXG MiMedx Group Sell-off TrendPairCorr
  0.46KA Kineta Inc Report 29th of March 2024 PairCorr
  0.46CALT Calliditas Therapeutics Financial Report 21st of May 2024 PairCorr
The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.
The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Armata Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Armata Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Armata Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Armata Pharmaceuticals Stock:
Check out the analysis of Armata Pharmaceuticals Correlation against competitors.
To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Armata Stock analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Money Managers
Screen money managers from public funds and ETFs managed around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Commodity Directory
Find actively traded commodities issued by global exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Bonds Directory
Find actively traded corporate debentures issued by US companies
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is Armata Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Armata Pharmaceuticals. If investors know Armata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Armata Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.91)
Revenue Per Share
0.126
Quarterly Revenue Growth
0.454
Return On Assets
(0.26)
Return On Equity
(34.39)
The market value of Armata Pharmaceuticals is measured differently than its book value, which is the value of Armata that is recorded on the company's balance sheet. Investors also form their own opinion of Armata Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Armata Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Armata Pharmaceuticals' market value can be influenced by many factors that don't directly affect Armata Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Armata Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Armata Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Armata Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.